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Abstract
Purpose: The aim of this study is to evaluate the effects of the metallic reservoir and the use of gas within the Aeroform™ tissue
expander with respect to the radiation dose distribution. Methods: Dosimetric effects of using a metallic reservoir within a
breast tissue expander during external beam radiotherapy were investigated. To view the internal components of the reservoir,
it was removed from the tissue expander and imaged on a Varian AS500 electronic portal imager. To calculate the relative den-
sity of each component within the reservoir, an ionization chamber within solid water was used to measure the dose and com-
pared to a simulation within the Pinnacle treatment planning system (TPS). To examine the relative dose profile along the
length of the reservoir, the reservoir was exposed on EBT3 film and analyzed using SNC Patient™. In-vivo Dosimetry was per-
formed using a RANDO® Woman phantom. Thermo-luminescent dosimeters were placed within the wax bolus enveloping the
tissue expander. Results: Imaging the reservoir on the electronic portal imager revealed it consists of 3 distinct components. The
densities assigned in the TPS, which resulted in calculated doses which matched the measured doses were; Section 1 = 0 g/cm3,
Section 2 = 2.8 g/cm3 and Section 3 = 0.7 g/cm3. Relative dose reductions were observed due to the metallic case; Section 1 =
20%, Section 2 = 40% and Section 3 = 30%. Entrance doses ranged from 2.39 - 2.53 Gy for both the medial and lateral beams.
Exit doses ranging from 1.10 - 1.71 Gy were observed in both beams. There was a significant difference in measured and calcu-
lated doses at exit locations in the beam. Conclusion: Dosimetric effects due to the metallic reservoir within the Aeroform
breast tissue expander have been demonstrated and have been observed to be significant. To increase the dosimetric accuracy
when contouring, individual components of the reservoir should be distinguished. Our in-vivo experiment showed that dose
homogeneity was difficult due to the metallic reservoir and we recommend stringent patient dose monitoring when using this
expander during radiotherapy.
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Introduction
Immediate reconstruction after a mastectomy in breast can-
cer patients may markedly improve a woman’s quality of life
by enhancing body image, cosmetic outcome, and overall
psychological well-being.1,2 Consequently, mastectomy or
nipple sparing mastectomy (NSM) combined with immediate
breast reconstruction with either temporary tissue expand-
er/implant reconstruction or autologous tissue reconstruc-
tion, has been performed for an increasing numbers of pa-
tients. However, the presence of a reconstruction may com-
plicate the planning for radiation therapy as well as increase
the risk of long-term complications related to radiotherapy
treatment, which may impact the cosmetic outcome.3-5 The
role of adjuvant post-mastectomy radiotherapy (PMRT) is
now well established for locally advanced and node positive
breast cancer with level 1 evidence from the Early Breast
Cancer Trialists’ Collaborative Group (EBCTCG) me-
ta-analysis demonstrating an improvement in loco-regional
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control and overall survival.6 Even patients with 1-3 nodes
will benefit from PMRT with outcome survival improved by
7.9% at 20 years. As such the decision to undergo immediate
reconstruction and the need to deliver PMRT will present
immediate and future challenges to both patients and their
care givers.
When a patient requires PMRT or where the role of external
RT is uncertain before mastectomy, a saline filled tissue ex-
pander may be placed at the time of definitive surgery. This
allows for re-expansion of collapsed breast skin and mainte-
nance of the skin envelope on the first stage of a two-stage
implant reconstruction or a delayed autologous reconstruc-
tion after radiation therapy while awaiting assessment of the
final pathology. If PMRT is recommended, radiation therapy
is delivered with the temporary tissue expander in place.
Gradual expansion of the skin is accomplished by the injec-
tion of saline into the expander using a metal-backed mag-
netically locatable port. This can be a lengthy process, in-
volving several disruptive and often uncomfortable saline
injections over weeks. In an effort to provide the patient
with a more comfortable, gradual tissue expansion process
that they control, a breast tissue expansion system consisting
of a CO2-filled tissue expander (AeroForm™) and a handheld
radio-frequency dosage controller has been devised. The
dosage controller communicates with the expander and al-
lows the patient to self-administer 10 cc doses of CO2 from a
reservoir within the expander 7 obviating needle punctures
to achieve expansion. The purpose of this investigation is to
evaluate the effects of the metallic reservoir and the use of
gas within the Aeroform™ tissue expander with respect to
the radiation dose distribution.
Methods and Materials
The Aeroform™ (manufactured by AirXpanders™) pa-
tient-controlled tissue expander consists of an anatomically
shaped outer silicone shell and an inner metallic reservoir of
compressed carbon dioxide. The surgeon and/or patient in-
creases the volume of the expander by using a wireless
handheld controller to release the carbon dioxide from the
metallic reservoir (Figure 1).
FIG. 1: An illustration of the AirXpander™ system taken from
http://www.airxpanders.com/.
The 850 cc expander model LP130-850 Large was used for
this study, with the outer shell expanded to 400 cc capacity.
The material of the metallic reservoir case is stainless steel.
The reservoir is unable to be opened and hence the internal
components, materials and its impact on the delivery of ra-
diation are unknown for the purpose of this study.
Dosimetric studies using film were performed using Gaf-
chromicTM EBT3 film 8, SNC Patient™ software v6.0 and
PTW RW3 solid water.9 SNC Patient™ by Sun Nuclear is a
software which provides tools for planar dose analysis. Gaf-
chromic™ EBT3 film is a self-developing, radiosensitive film.
Ion chamber measurements were performed without the
outer shell using a Scanditronix™ CC13 ionization chamber 10
and PTW RW3 solid water.
In-vivo dosimetry measurements were performed using
LiF:Mg thermo-luminescent dosimeters (TLD), a RANDO® 11
woman and fabric-backed gel. TLD results were later com-
pared to dose calculations in Pinnacle3™ v9.2 using the Col-
lapsed-Cone Convolution (CCC) algorithm.
To view the internal components of the metallic reservoir,
the reservoir was removed from the tissue expander unit
(Figure 2) and exposed on a Varian AS500 portal dosimeter.
FIG. 2: The metallic reservoir and the signal receiver removed from
within the AirXpander breast tissue expander system.
Pseudo Density of the Reservoir Components
The dosimetric accuracy around the metallic reservoir mod-
elled in the treatment planning system is significantly de-
pendent on accurate contouring and assigning the correct
densities. In this scenario, it was difficult to assign a density to
an unknown component of an unknown material. Therefore,
for the purpose of an initial dose calculation, an arbitrary
estimate of the density was assigned to each component of the
reservoir. The metallic stainless steel casing was assigned a
density of 8.0 g/cm3 and gas was assigned a density of 0.0
g/cm3. A CC13 ionization chamber was placed in RW3 solid
water at 1.5 cm depth, 100 cm source-to-surface distance
(SSD) to the surface of the phantom. A single 6 MV beam at
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gantry 0° delivered 100 monitor units (MU) with a field size
of 10 cm x 10 cm. The metallic reservoir was removed from
the tissue expander unit and placed flat on the solid water.
The chamber was placed directly under each component of
the reservoir and a measurement was obtained (Figure 3).
Using an MV image of the reservoir as a visual guide, the
contoured reservoir in the treatment planning system was
then assigned a density, which resulted in a planned dose that
matched the measured reading.
FIG. 3: An ion chamber placed in RW3 directly under the gas
chamber of the metallic reservoir.
Film Dosimetry Measurements
To obtain a dose profile and measure the attenuation of the
beam through the metallic reservoir, EBT3 film was placed in
solid water at 1.5 cm depth. A single 6 MV beam at gantry 0°
and 100cm SSD, delivered 200 MU for a 15 x 15 cm field size
(Figure 4). The exposed film was scanned into the computer
and analysed using SNC Patient™ software. The breast ex-
pander unit and reservoir were still intact was placed on the
surface with the reservoir at the centre of the field.
FIG. 4: The Aeroform™ breast tissue expander system on RW3 solid
water with the metallic reservoir at the beam centre.
In-Vivo Dosimetry Using a RANDO® Woman
A RANDO® woman was simulated on a breast board with the
Aeroform™ breast tissue expander unit attached as shown in
Figure 5. The expander was placed on the RANDO® with the
length of the metallic reservoir in the long axis in the trans-
verse direction.
FIG. 5: The Aeroform™ breast tissue expander system with wax bolus
on a RANDO® woman.
An average of 1.5 cm of thermoplastic wax was moulded over
the expander to simulate breast tissue. The RANDO® woman
was scanned using computed tomography (CT) and imported
into the treatment planning system. The PTV was created
from a contour of the wax bolus, minus the breast tissue
expander, contracted 5 mm from the bolus surface and 5 mm
from the lung and posterior beam edge (Figure 6).
FIG. 6: An illustration of the mean PTV defined in this experiment.
A 6 MV parallel-opposed oblique technique was used to de-
liver 200 MU. TLDs were placed beneath the metallic ex-
pander and on the surface of the expander to measure the skin
entrance and exit dose (Figure 7). This experiment was re-
peated twice and the results were averaged.
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FIG. 7: A CT image slice of the Aeroform breast tissue expander
system. The treatment comprises of a pair of parallel-opposed beams.
For each beam, the entrance dose at two positions and exit dose at
two positions are measured.
Results
Figure 8 shows an image acquired by a Varian AS500 portal
dosimeter, which shows the internal components of the me-
tallic reservoir. The manufacturer has not disclosed the exact
function of each component, however it is assumed the
compressed gas is stored in the chamber indicated by the
dark void in the first section of the reservoir. The second and
third section of the reservoir forms the components which
allow for the compressed gas to be released into the expand-
er. Each section is numbered accordingly for the purpose of
the following experiments.
FIG. 8: An image of the internal components of the metallic reser-
voir within the AirXpander™ system, taken by a Varian™ AS500
portal dosimeter.
Pseudo Density of the Reservoir Components
The density assigned to Sections 2 and 3, which resulted in
matched calculated and measured readings, were 2.8 g/cm3
and 0.7 g/cm3 respectively. These results are tabulated in
Table 1.
Film Dosimetry Measurements
The scanned film was analysed in absolute dose mode and
normalized to 200 cGy. Figure 10 shows the dose profile
along the length of the metallic reservoir as shown by the
green line in Figure 9.
FIG. 9: A film scan imported into SNC Patient software.
A dose reduction of approximately 20% was observed at the
tip of the gas chamber. A maximum dose reduction of 40%
was observed in the high density region at Section 2 and a
reduction of 30% was observed in Section 3 of the metallic
reservoir. The observed reductions in dose were consistent
with data previously published.12
FIG. 10: A line dose profile of the metallic reservoir using Relative
Dose mode.
In-Vivo Dosimetry Using a RANDO® Woman
In-vivo measurements using TLDs were performed and
compared with Pinnacle3™ v9.2. TLD were placed in posi-
tions as shown in Figure 6. Measurements for this experi-
ment are summarized in Table 2. Entrance doses ranged from
2.39 – 2.53 Gy for both the medial and lateral beams. Exit
doses ranging from 1.10 to 1.71 Gy were observed in both
beams.
Percentage differences between measured and calculated
doses varied from -1.8 to 14.6%. For the medial beam at the
locations 2 and 4, higher differences between measured and
calculated doses were observed compared to locations 1 and
3. This may be due to either inaccurate positioning of the
TLD on a curved surface or contributed by the uncertainty
in modelling at the air/tissue interface. A higher difference
between both calculated and measured doses were observed
in the lateral exit beam at locations 1 and 2 compared to
entrance locations 3 and 4. This may be due to the uncer-
tainty contributed to the attenuation of the beam as it passes
through high density materials. Moni et al. has published an
average difference between the measured and calculated
dose of -3.0% 12 using OSLDs placed at a similar location to
the lateral beam exit 1 and 2.
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1 1.50 0 0.92 0.92 0.52
2 3.06 2.8 0.73 0.73 0.58
3 3.06 0.7 0.82 0.82 0.57
TABLE 2: Measured TLD doses compared to Pinnacle3™ v9.2 dose
calculations.




































Damast et al.13 has found that Magna-SiteTM disc ports used
in McGhan Style 133 14 breast expanders can reduce the
beam transmission to as much as 78% for a 6 MV beam for
certain orientations of the magnet. Thompson et al. 15 have
also reported that the transmission of the radiation beam was
reduced to 70% due to the Magna-Site™ disc port. However,
Moni et al.12 showed that the presence of a metallic port in
the tissue expander does not significantly contribute to the
high complication rates. This is mainly because any in-
creased dose due to the metallic port is observed in the im-
mediate vicinity of the port (< 7 mm) where the effect is
mostly observed in the expander volume and not the chest
wall. However, the shape of the metallic reservoir used in
the AeroformTM is cylindrical, which may present different
transmission values which are dependent on the thickness of
metallic material the beam traverses. Also, the location of
the metallic reservoir in the AeroformTM is proximal relative
to the chest wall compared to Magna-SiteTM disc ports used
in the McGhan Style 133 breast tissue expander.
In this experiment, the sample provided was only expanded
with 400 cc of gas. Full expansion of 850 cc of gas would
have been preferred. This presented a slight difficulty in
maintaining the rigidity of the expander during experiments
and would have reduced the uncertainty of TLD positioning.
Since the Aeroform™ breast tissue expander is expanded
with gas, the dose was prescribed to the mean planning tar-
get volume, which is the tissue around the expander. This
method increases the dose inhomogeneity, which contrib-
utes to high dose gradients in the overlying tissue. One area
of concern would be the increase of scatter into the breast
tissue and chest wall from having a relatively large high den-
sity material in the tissue expander. Combined with the lack
of tissue equivalent material in the vicinity of the metallic
reservoir, this may lead to significant hot spots during radi-
otherapy especially in the overlying breast tissue.
Upon observing the dose distribution (Figure 11), the TLDs
were placed in regions of high gradients due to the scattering
effects of the metallic reservoir. This may have contributed
to increased differences between calculated and measured
doses. In this experiment, smaller differences between
measured and calculated doses were observed underneath
the reservoir where the dose region was more homogenous
compared to all other locations. This indicated that areas
adjacent to gas were more difficult to verify dosimetrically.
FIG. 11: A dose distribution of the Aeroform™ breast tissue expander
unit in this experiment.
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Conclusion
Dosimetric effects due to the metallic reservoir within the
Aeroform breast tissue expander have been demonstrated
and have been observed to be significant. Our investigation
with the internal components of the metallic reservoir aims
to increase the accuracy of assigning the physical density and
physical contouring of the metallic reservoir in the treat-
ment planning system. Our in-vivo dosimetry experiment
with the RANDO® demonstrated that dose homogeneity
may be difficult to achieve in the surrounding tissue. In ad-
dition it may be difficult to verify the planned dose due to
the scattering effects of the reservoir. The Aeroform™ is a
novel expander that may be increasingly utilised due to its
inherent simplicity and ease of use. As such we welcome its
introduction but recommend stringent patient dose moni-
toring when utilised in patients undergoing radiotherapy.
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